Hamlet BioPharma マネジメント
マネジメント 基準チェック /04
現在、CEO に関する十分な情報がありません。
主要情報
Petter Lindqvist
最高経営責任者
n/a
報酬総額
CEO給与比率 | n/a |
CEO在任期間 | 1.1yrs |
CEOの所有権 | n/a |
経営陣の平均在職期間 | データなし |
取締役会の平均在任期間 | データなし |
経営陣の近況
Recent updates
Is Hamlet Pharma (NGM:HAMLET B) In A Good Position To Invest In Growth?
Jul 04Here's Why We're Watching Hamlet Pharma's (NGM:HAMLET B) Cash Burn Situation
Mar 04We Think Hamlet Pharma (NGM:HAMLET B) Can Afford To Drive Business Growth
Nov 10We Think Hamlet Pharma (NGM:HAMLET B) Can Easily Afford To Drive Business Growth
Jun 17Companies Like Hamlet Pharma (NGM:HAMLET B) Are In A Position To Invest In Growth
Oct 12Will Hamlet Pharma (NGM:HAMLET B) Spend Its Cash Wisely?
Mar 17CEO(最高経営責任者
Petter Lindqvist
1.1yrs
在職期間
Mr. Petter Segelman Lindqvist serves as Chief Executive Officer of Isofol Medical AB (publ) since January 09, 2024. He is Chief Executive Officer of Hamlet BioPharma AB (publ) (formerly known as Hamlet Pha...